A Green Sign – Lifestyle
Author:
BridgeBio Pharma, Inc.
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
April 22, 2026
Acoramidis Significantly Reduces the Risk of All-Cause and Cardiovascular Mortality in Patients with ATTR-CM through Month 54
March 30, 2026
BridgeBio Submits NDA to FDA for BBP-418 for Individuals Living with LGMD2I/R9
March 30, 2026
BridgeBio to Present Long-Term Efficacy and Safety Data from the ATTRibute-CM OLE Trial at the ACC Annual Scientific Sessions
March 23, 2026
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
March 20, 2026
BBP-418 Demonstrates Consistent Efficacy and Favorable Safety Profile in Phase 3 FORTIFY Interim Analysis in LGMD2I/R9
March 11, 2026
BridgeBio to Present Additional Data from the Phase 3 FORTIFY Trial at the 2026 MDA Clinical & Scientific Conference
March 6, 2026
BridgeBio Reports Fourth Quarter and Full Year 2025 Financial Results and Commercial Updates
March 4, 2026